Merck looks for a return on its Lynparza investment
Merck & Co has sunk billions into Lynparza, but its Keytruda combo plan, which it is funding solely, just got off to a rocky start.
Eisai leaves Biogen holding the Aduhelm baby
The Japanese group doubles down on lecanemab while somehow disentangling itself from the Aduhelm mess.
Amgen follows Sanofi into a new dermatitis mechanism
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
Another complement factor enters the deal-making frame
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Biogen pays $560m for an unproven Parkinson’s mechanism
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Morphosys gets a major tafasitamab endorsement
Incyte hands across $750m up front and buys $150m of Morphosys equity for rights to the anti-CD19 project.
